News

The company has reported a net loss of $6.65m, or $0.07 loss per diluted share, compared to net loss of $15.95m or $0.17 loss per diluted share, for

The company has reported a net income of $431,000, or $0.01 per diluted share, compared to net income of $199.81m or $0.29 loss per diluted share, for the

The test is said to be in development for the European and US in vitro diagnostic (IVD) market. Dynabeads MyOne SILANE are monosized, magnetic beads that bind to

Selvita develops medicines for central nervous system, oncology and autoimmune disorders as well as provision of non-clinical research services. Proceeds from the financing will be used primarily for

Developed in collaboration with the University of Oslo, Norway, Albufuse Flex technology will facilitate manipulation based on this FcRn-albumin interaction, enabling a tunable half-life that offers control and

Avandia (rosiglitazone maleate) is an oral antidiabetic agent which acts primarily by increasing insulin sensitivity. The cases were filed against GSK as studies linked the drug to increased

The novel small molecule scaffolds were identified using COTI’s drug discovery technology CHEMSAS. CHEMSAS uses a series of predictive computer models to identify compounds most likely to be

The company reported a net loss of $32.67m, or $0.3 per diluted share, compared to a net income of $11.46m, or $0.11 per diluted share, for the same

The increase in revenues was due to primarily funding from the company’s collaborative partner Les Laboratoires Servier for XOMA 052 development and increased funding under the company’s contracts